EARNEST Partners’s Ionis Pharmaceuticals IONS Stock Holding History

EARNEST Partners’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-49	Closed	-$2.22K	–	679
2023 Q3	$2.22K	Hold	49	–	–	﹤0.01%	981
2023 Q2	$2.01K	Hold	49	–	–	﹤0.01%	992
2023 Q1	$1.75K	Hold	49	–	–	﹤0.01%	1005
2022 Q4	$1.85K	Hold	49	–	–	﹤0.01%	1007
2022 Q3	$2K	Hold	49	–	–	﹤0.01%	976
2022 Q2	$2K	Hold	49	–	–	﹤0.01%	998
2022 Q1	$2K	Hold	49	–	–	﹤0.01%	1023
2021 Q4	$1K	Hold	49	–	–	﹤0.01%	1106
2021 Q3	$2K	Hold	49	–	–	﹤0.01%	1030
2021 Q2	$2K	Hold	49	–	–	﹤0.01%	1037
2021 Q1	$2K	Hold	49	–	–	﹤0.01%	1033
2020 Q4	$3K	Hold	49	–	–	﹤0.01%	938
2020 Q3	$2K	Hold	49	–	–	﹤0.01%	961
2020 Q2	$3K	Hold	49	–	–	﹤0.01%	867
2020 Q1	$2K	Hold	49	–	–	﹤0.01%	890
2019 Q4	$3K	Hold	49	–	–	﹤0.01%	922
2019 Q3	$3K	Hold	49	–	–	﹤0.01%	892
2019 Q2	$3K	Hold	49	–	–	﹤0.01%	912
2019 Q1	$4K	Hold	49	–	–	﹤0.01%	823
2018 Q4	$3K	Hold	49	–	–	﹤0.01%	866
2018 Q3	$3K	Hold	49	–	–	﹤0.01%	929
2018 Q2	$2K	Hold	49	–	–	﹤0.01%	1026
2018 Q1	$2K	Hold	49	–	–	﹤0.01%	997
2017 Q4	$2K	Buy	+49	New	+$2.69K	﹤0.01%	994
2017 Q1	–	Sell	-49	Closed	-$2K	–	558
2016 Q4	$2K	Buy	+49	New	+$1.94K	﹤0.01%	925

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

EARNEST Partners's IONS Position: Q4 2023 in Review

EARNEST Partners sold out of Ionis Pharmaceuticals (IONS) in Q4 2023, closing a stake of 49 shares — an estimated $2.22K sold.

EARNEST Partners first reported a position in IONS in Q4 2016 and held it in 25 quarters. The position peaked at $4K in Q1 2019. 363 funds tracked by Wall St. Rank hold IONS as of Q4 2023.

EARNEST Partners reported no remaining Ionis Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
EARNEST Partners sold 49 Ionis Pharmaceuticals shares in Q4 2023, an estimated $2.22K.
EARNEST Partners first reported a position in Ionis Pharmaceuticals in Q4 2016 and held it in 25 quarters.
EARNEST Partners's Ionis Pharmaceuticals position peaked at $4K in Q1 2019.
363 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2023.

Based on EARNEST Partners's 13F filing for Q4 2023, filed 14 Feb 2024.